Knight Therapeutics (TSX: GUD) has announced that its new drug submission (NDS) for CREXONT—a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson’s disease—has...
Senti Bio (NASDAQ: SNTI) has announced the appointment of entrepreneurial leader and investor Bryan Baum to its board of directors (BOD). Mr. Baum is the co-founder and managing partner of K5 Global. His portfolio...
Ekso Bionics (NASDAQ: EKSO) has announced the launch of eksoUniversity, a new platform providing continuing education (CE) courses to physical therapists (PTs) and physical therapy assistants (PTAs) across the U.S. Most...
Cognition Therapeutics (NASDAQ: CGTX) has announced that James Edward Galvin, MD, MPH, will present results from the Phase 2 SHIMMER study of zervimesine (CT1812) in dementia with Lewy bodies (DLB) during an oral...
Revelation Biosciences (NASDAQ: REVB) has announced the completion of dosing for its PRIME Phase 1b study of escalating doses of intravenously administered Gemini—a proprietary formulation of phosphorylated hexaacyl...
Lake Street Capital Markets senior research analyst, Ben Haynor, issued a research note today on Profound Medical (NASDAQ:PROF; TSX:PRN), reiterating his ‘buy’ rating and $11 target price on the company’s stock...
In the latest episode of consulting company Cell One Partners’ video series—Cell One Insights—on cell and gene therapy, Stephen Chang, PhD—a human geneticist and partner at Cell One Partners—shares insights from his 40...
Iovance Biotherapeutics (NASDAQ: IOVA) has announced the appointment of Corleen Roche as chief financial officer (CFO), effective August 6, 2025. Ms. Roche brings three decades of biotech and life sciences industry...
BiomX (NYSE: PHGE) has announced the initiation of patient dosing in its Phase 2b trial evaluating BX004 for the treatment of cystic fibrosis (CF) patients with chronic pulmonary infections caused by Pseudomonas...
Firefly Neuroscience (NASDAQ: AIFF) has announced its continued collaboration with Prof. Christian Schaaf, MD, Director of the Institute of Human Genetics at Heidelberg University Hospital and Chairman of Human Genetics...
MiNK Therapeutics (NASDAQ: INKT) has highlighted a publication in the peer-reviewed journal Oncogene describing a complete and durable remission in a patient with metastatic, treatment refractory testicular cancer...
Quince Therapeutics (NASDAQ: QNCX) has announced the appointment of leading immunologist, Hassan Abolhassani, MD, PhD, to its scientific advisory board (SAB). Dr. Abolhassani currently serves as assistant professor of...